The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre Study

CNS Drugs

Volumn 23, Issue 7, 2009, Pages 615-625

  Garcia, Esther ^a   Robert, Marta ^a   Peris, Francesc ^a   Nakamura, Hiroshi ^b   Sato, Noriko ^b   Terazawa, Yoshikatsu ^b  

^a Laboratorios Almirall SA ^*  (Spain)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLONANSERIN; HALOPERIDOL; PROLACTIN;

ADULT; AGITATION; AKATHISIA; ANXIETY DISORDER; ARTICLE; BRADYCARDIA; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE RIGIDITY; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PARALLEL DESIGN; PARKINSONISM; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; PIPERAZINES; PIPERIDINES; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 67649390905     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/00023210-200923070-00006     Document Type: Article

References (32)

1. Kane JM. Schizophrenia. N Engl J Med 1996; 334 (1): 34-41
2. Kane JM. Management strategies for the treatment of schizophrenia. J Clin Psychiatry 1999; 60 Suppl. 12: 13-7
3. Bridler R, Umbricht D. Atypical antipsychotics in the treatment of schizophrenia. Swiss Med Weekly 2003; 133: 63-76
4. Meltzer HY. What's atypical about atypical antipsychotics? Curr Opin Pharmacol 2004; 4 (1): 53-7
5. Meltzer HY, Ii Z, Kaneda Y, et al. Serotonin receptors: their key role in drugs to treat schizophrenia. Progr Neuro-Psychopharmacol Biol Psychiatry 2003; 27: 1159-72
6. Collaborative Working Group on Clinical Trial Evaluations. Adverse effects of the atypical antipsychotics. J Clin Psychiatry 1998; 59 Suppl. 12: 17-22
7. Uçok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry 2008; 7: 58-62
8. Oka M, Noda Y, Ochi Y, et al. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J Pharmacol Exp Ther 1993; 264: 158-65
9. Une T, Kurumiya S. Pharmacological profile of blonanserin [in Japanese]. Jpn J Clin Psychopharmacol 2007; 10: 1263-72
10. Murasaki M. Long-term clinical study of blonanserin for schizophrenia (Kanagawa region clinical psychopharmacology study group) [in Japanese]. Jpn J Clin Psychopharmacol 2007; 10: 2241-57
11. Kinoshita T. Long-term clinical study of blonanserin for schizophrenia (Japan-wide study) [in Japanese]. Jpn J Clin Psychopharmacol 2008; 11: 135-53
12. Murasaki M. Clinical evaluation of blonanserin for schizophrenia: a double-blind trial comparing blonanserin with haloperidol [in Japanese]. Jpn J Clin Psychopharmacol 2007; 10: 2059-79
13. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277 (11): 925-6
14. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV-TR). Fourth text revision ed. Washington, DC: American Psychiatric Association, 2000
15. Bell M, Milstein R, Beam-Goulet J, et al. The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale: reliability, comparability, and predictive validity. J Nerv Ment Dis 1992; 180 (11): 723-8
16. Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: US Goverment Printing Office, 1976
17. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia (CPMP/EWP/559/95) [online]. London: The European Agency for the Evaluation of Medicinal Products, 1998 Feb. Available from URL: http://www.emea.europa.ed/pdfs/human/ewp/055995en.pdf [Accessed 2009 Apr 10]
18. Blonanserin investigator's brochure. Osaka: Dainippon Sumitomo Pharma Co., Ltd, 2006. (Data on file)
19. Schooler NR. New antipsychotic medications: strategies for evaluation and selected findings. Schizophr Res 1997; 27 (2-3): 249-59
20. Collaborative Working Group on Clinical Trial Evaluations. Clinical development of atypical antipsychotics: research design and evaluation. J Clin Psychiatry 1998; 59 Suppl. 12: 10-6
21. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371-6
22. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334: 1-100
23. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-9
24. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-6
25. Snedecor GW, Cochran WG. Statistical methods. 8th ed. Ames (IA): Iowa State University Press, 1989
26. Winer BJ, Brown DR, Kenneth KM. Statistical principles in experimental design. 3rd ed. New York: McGraw-Hill, 1991
27. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons, 1989
28. Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol 2008; 23 (3): 201-9
29. Knegtering H, van den Bosch R, Castelein S, et al. Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin? Psychoneuroendocrinology 2008; 33 (6): 711-7
30. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156 (11): 1686-96
31. Henderson DC. Weight gain with atypical antipsychotics: evidence and insights. J Clin Psychiatry 2007; 68 Suppl. 12: 18-26
32. Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain. JAMA 2008; 299 (2): 185-93